Supportive Care in Cancer

, Volume 17, Issue 3, pp 231–240 | Cite as

Complications of traditional Chinese/herbal medicines (TCM)—a guide for perplexed oncologists and other cancer caregivers

Review Article

Abstract

Introduction

Cancer patients often seek complementary or alternative medicines to supplement or replace treatments prescribed by licensed medical practitioners. Traditional Chinese/herbal medicine (TCM) is a popular complementary intervention among cancer patients of Asian ethnicity, many of whom take it during their conventional treatment. Few of these patients inform their doctors, however, creating a risk of unexpected sequelae arising from either pharmacologic toxicity, unsuitable dosing, interactions with anti-cancer drugs or other medications, adulteration, or idiosyncratic reactions. If unrecognized, these problems may be misattributed to conventional treatment toxicity or disease progression, and remedial action may be inappropriate or delayed.

Goals of work

The purpose of this review is to help oncologists recognize the common presentations of TCM-related problems in cancer patients—such as abnormal liver function tests, unexpectedly severe myelosuppression, hemostatic defects, renal functional impairment, or suspected drug interactions—and to teach strategies by which these problems can be anticipated, prevented, or managed.

Conclusion

Through sensitive understanding of the reasons favoring TCM usage, oncologists can gain the trust and respect of their TCM-using patients while ensuring the safety and efficacy of conventional anticancer treatments.

Keywords

Complementary and alternative medicine Drug toxicity Cancer chemotherapy Herbs 

Notes

Acknowledgments

We thank Professor Cyrus Kumana for critical review of the manuscript. No funding was provided for this analysis.

References

  1. 1.
    Agbabiaka TB, Savovic J, Ernst E (2008) Methods for causality assessment of adverse drug reactions: a systematic review. Drug Saf 31:21–37PubMedGoogle Scholar
  2. 2.
    Aithal GP (2005) When is a herb a drug. Eur J Gastroenterol Hepatol 17:391–393PubMedGoogle Scholar
  3. 3.
    Ashby MA, Kissane DW, Beadle GF, Rodger A (1996) Psychosocial support, treatment of metastatic disease and palliative care. Med J Aust 164:43–49PubMedGoogle Scholar
  4. 4.
    Bajwa RP, Cant AJ, Abinun M, Flood TJ, Hodges S, Hale JP, Skinner R (2003) Recombinant tissue plasminogen activator for treatment of hepatic veno-occlusive disease following bone marrow transplantation in children: effectiveness and a scoring system for initiating treatment. Bone Marrow Transplant 31:591–597PubMedGoogle Scholar
  5. 5.
    Batey RG, Bensoussan A, Fan YY, Bollipo S, Hossain MA (1998) Preliminary report of a randomized, double-blind placebo-controlled trial of a Chinese herbal medicine preparation CH-100 in the treatment of chronic hepatitis C. J Gastroenterol Hepatol 13:244–247PubMedCrossRefGoogle Scholar
  6. 6.
    Boon HS, Olatunde F, Zick SM (2007) Trends in complementary/alternative medicine use by breast cancer survivors: comparing survey data from 1998 and 2005. BMC Womens Health 7:4PubMedGoogle Scholar
  7. 7.
    Brazier NC, Levine MA (2003) Drug–herb interaction among commonly used conventional medicines: a compendium for health care professionals. Am J Ther 10:163–169PubMedGoogle Scholar
  8. 8.
    Canter PH, Ernst E (2004) Herbal supplement use by persons aged over 50 years in Britain: frequently used herbs, concomitant use of herbs, nutritional supplements and prescription drugs, rate of informing doctors and potential for negative interactions. Drugs Aging 21:597–605PubMedGoogle Scholar
  9. 9.
    Cassileth BR, Deng G (2004) Complementary and alternative therapies for cancer. Oncologist 9:80–89PubMedGoogle Scholar
  10. 10.
    Chalandon Y, Roosnek E, Mermillod B, Newton A, Ozsahin H, Wacker P, Helg C, Chapuis B (2004) Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 10:347–354PubMedGoogle Scholar
  11. 11.
    Chamberlain JJ, Abolnik IZ (1997) Pulmonary edema following a licorice binge. West J Med 167:184–185PubMedGoogle Scholar
  12. 12.
    Chen M, Su M, Zhao L, Jiang J, Liu P, Cheng J, Lai Y, Liu Y, Jia W (2006) Metabonomic study of aristolochic acid-induced nephrotoxicity in rats. J Proteome Res 5:995–1002PubMedGoogle Scholar
  13. 13.
    Chiu SW, Wang ZM, Leung TM, Moore D (2000) Nutritional value of ganoderma extract and assessment of its genotoxicity and antigenotoxicity using comet assays of mouse lymphocytes. Food Chem Toxicol 38:173–178PubMedGoogle Scholar
  14. 14.
    Chrystal K, Allan S, Forgeson G, Isaacs R (2003) The use of complementary/alternative medicine by cancer patients in a New Zealand regional cancer treatment centre. N Z Med J 116:U296PubMedGoogle Scholar
  15. 15.
    Chu DT, Wong WL, Mavligit GM (1988) Immunotherapy with Chinese medicinal herbs. II. Reversal of cyclophosphamide-induced immune suppression by administration of fractionated Astragalus membranaceus in vivo. J Clin Lab Immunol 25:125–129PubMedGoogle Scholar
  16. 16.
    Correa-Velez I, Clavarino A, Eastwood H (2005) Surviving, relieving, repairing, and boosting up: reasons for using complementary/alternative medicine among patients with advanced cancer: a thematic analysis. J Palliat Med 8:953–961PubMedGoogle Scholar
  17. 17.
    Cosyns JP, Jadoul M, Squifflet JP, De Plaen JF, Ferluga D, van Ypersele de Strihou C (1994) Chinese herbs nephropathy: a clue to Balkan endemic nephropathy. Kidney Int 45:1680–1688PubMedGoogle Scholar
  18. 18.
    Dai N, Yu YC, Ren TH, Wu JG, Jiang Y, Shen LG, Zhang J (2007) Gynura root induces hepatic veno-occlusive disease: a case report and review of the literature. World J Gastroenterol 13:1628–1631PubMedGoogle Scholar
  19. 19.
    Deng G, Cassileth BR, Yeung KS (2004) Complementary therapies for cancer-related symptoms. J Support Oncol 2:419–426 discussion 427–419PubMedGoogle Scholar
  20. 20.
    Donovan JL, DeVane CL, Chavin KD, Taylor RM, Markowitz JS (2003) Siberian ginseng (Eleutheroccus senticosus) effects on CYP2D6 and CYP3A4 activity in normal volunteers. Drug Metab Dispos 31:519–522PubMedGoogle Scholar
  21. 21.
    Dukes MN (1978) Ginseng and mastalgia. Br Med J 1:1621PubMedGoogle Scholar
  22. 22.
    Eastwood MA, Brydon WG, Anderson DM (1984) The effects of dietary gum tragacanth in man. Toxicol Lett 21:73–81PubMedGoogle Scholar
  23. 23.
    Ernst E (2000) The role of complementary and alternative medicine in cancer. Lancet Oncol 1:176–180PubMedGoogle Scholar
  24. 24.
    Ernst E (2004) Risks of herbal medicinal products. Pharmacoepidemiol Drug Saf 13:767–771PubMedGoogle Scholar
  25. 25.
    Farese RV Jr., Biglieri EG, Shackleton CH, Irony I, Gomez-Fontes R (1991) Licorice-induced hypermineralocorticoidism. N Engl J Med 325:1223–1227PubMedGoogle Scholar
  26. 26.
    Feldmeyer N, Schmeiser HH, Muehlbauer KR, Belharazem D, Knyazev Y, Nedelko T, Hollstein M (2006) Further studies with a cell immortalization assay to investigate the mutation signature of aristolochic acid in human p53 sequences. Mutat Res 608:163–168PubMedGoogle Scholar
  27. 27.
    Fessenden JM, Wittenborn W, Clarke L (2001) Gingko biloba: a case report of herbal medicine and bleeding postoperatively from a laparoscopic cholecystectomy. Am Surg 67:33–35PubMedGoogle Scholar
  28. 28.
    Frenkel M, Ben-Arye E, Baldwin CD, Sierpina V (2005) Approach to communicating with patients about the use of nutritional supplements in cancer care. South Med J 98:289–294PubMedGoogle Scholar
  29. 29.
    Fu PP, Xia Q, Lin G, Chou MW (2004) Pyrrolizidine alkaloids—genotoxicity, metabolism enzymes, metabolic activation, and mechanisms. Drug Metab Rev 36:1–55PubMedGoogle Scholar
  30. 30.
    Gerber B, Scholz C, Reimer T, Briese V, Janni W (2006) Complementary and alternative therapeutic approaches in patients with early breast cancer: a systematic review. Breast Cancer Res Treat 95:199–209PubMedGoogle Scholar
  31. 31.
    Goel A, Boland CR, Chauhan DP (2001) Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells. Cancer Lett 172:111–118PubMedGoogle Scholar
  32. 32.
    Greenspan EM (1983) Ginseng and vaginal bleeding. Jama 249:2018PubMedGoogle Scholar
  33. 33.
    Grollman AP, Shibutani S, Moriya M, Miller F, Wu L, Moll U, Suzuki N, Fernandes A, Rosenquist T, Medverec Z, Jakovina K, Brdar B, Slade N, Turesky RJ, Goodenough AK, Rieger R, Vukelic M, Jelakovic B (2007) Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci U S A 104:12129–12134PubMedGoogle Scholar
  34. 34.
    Guh JY, Chen HC, Tsai JF, Chuang LY (2007) Herbal therapy is associated with the risk of CKD in adults not using analgesics in Taiwan. Am J Kidney Dis 49:626–633PubMedGoogle Scholar
  35. 35.
    Guo R, Canter PH, Ernst E (2007) A systematic review of randomised clinical trials of individualised herbal medicine in any indication. Postgrad Med J 83:633–637PubMedGoogle Scholar
  36. 36.
    Hammond TG, Whitworth JA (1981) Adverse reactions to ginseng. Med J Aust 1:492PubMedGoogle Scholar
  37. 37.
    Harada T, Ohtaki E, Misu K, Sumiyoshi T, Hosoda S (2002) Congestive heart failure caused by digitalis toxicity in an elderly man taking a licorice-containing Chinese herbal laxative. Cardiology 98:218PubMedGoogle Scholar
  38. 38.
    Hlubocky FJ, Ratain MJ, Wen M, Daugherty CK (2007) Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials: a study of prognosis, quality of life, and preferences for decision making. J Clin Oncol 25:548–554PubMedGoogle Scholar
  39. 39.
    Holmes TH, Rahe RH (1967) The social readjustment rating scale. J Psychosom Res 11:213–218PubMedGoogle Scholar
  40. 40.
    Hsieh TC, Lu X, Chea J, Wu JM (2002) Prevention and management of prostate cancer using PC-SPES: a scientific perspective. J Nutr 132:3513S–3517SPubMedGoogle Scholar
  41. 41.
    Huxtable RJ (1990) Activation and pulmonary toxicity of pyrrolizidine alkaloids. Pharmacol Ther 47:371–389PubMedGoogle Scholar
  42. 42.
    Ishizaki T, Sasaki F, Ameshima S, Shiozaki K, Takahashi H, Abe Y, Ito S, Kuriyama M, Nakai T, Kitagawa M (1996) Pneumonitis during interferon and/or herbal drug therapy in patients with chronic active hepatitis. Eur Respir J 9:2691–2696PubMedGoogle Scholar
  43. 43.
    Janetzky K, Morreale AP (1997) Probable interaction between warfarin and ginseng. Am J Health Syst Pharm 54:692–693PubMedGoogle Scholar
  44. 44.
    Kimby CK, Launso L, Henningsen I, Langgaard H (2003) Choice of unconventional treatment by patients with cancer. J Altern Complement Med 9:549–561PubMedGoogle Scholar
  45. 45.
    Kumar NB, Allen K, Bell H (2005) Perioperative herbal supplement use in cancer patients: potential implications and recommendations for presurgical screening. Cancer Control 12:149–157PubMedGoogle Scholar
  46. 46.
    Kwok Y, Ng KF, Li CC, Lam CC, Man RY (2005) A prospective, randomized, double-blind, placebo-controlled study of the platelet and global hemostatic effects of Ganoderma lucidum (Ling-Zhi) in healthy volunteers. Anesth Analg 101:423–426 table of contentsPubMedGoogle Scholar
  47. 47.
    Lam AY, Elmer GW, Mohutsky MA (2001) Possible interaction between warfarin and Lycium barbarum L. Ann Pharmacother 35:1199–1201PubMedGoogle Scholar
  48. 48.
    Li M, Handa S, Ikeda Y, Goto S (2001) Specific inhibiting characteristics of tetramethylpyrazine, one of the active ingredients of the Chinese herbal medicine ‘Chuanxiong,’ on platelet thrombus formation under high shear rates. Thromb Res 104:15–28PubMedGoogle Scholar
  49. 49.
    Lord GM, Cook T, Arlt VM, Schmeiser HH, Williams G, Pusey CD (2001) Urothelial malignant disease and Chinese herbal nephropathy. Lancet 358:1515–1516PubMedGoogle Scholar
  50. 50.
    Lord GM, Tagore R, Cook T, Gower P, Pusey CD (1999) Nephropathy caused by Chinese herbs in the UK. Lancet 354:481–482PubMedGoogle Scholar
  51. 51.
    Manusirivithaya S, Sripramote M, Tangjitgamol S, Sheanakul C, Leelahakorn S, Thavaramara T, Tangcharoenpanich K (2004) Antiemetic effect of ginger in gynecologic oncology patients receiving cisplatin. Int J Gynecol Cancer 14:1063–1069PubMedGoogle Scholar
  52. 52.
    Martena MJ, van der Wielen JC, van de Laak LF, Konings EJ, de Groot HN, Rietjens IM (2007) Enforcement of the ban on aristolochic acids in Chinese traditional herbal preparations on the Dutch market. Anal Bioanal Chem 389:263–275PubMedGoogle Scholar
  53. 53.
    Martinez-Mir I, Rubio E, Morales-Olivas FJ, Palop-Larrea V (2004) Transient ischemic attack secondary to hypertensive crisis related to Panax ginseng. Ann Pharmacother 38:1970PubMedGoogle Scholar
  54. 54.
    McCulloch M, See C, Shu XJ, Broffman M, Kramer A, Fan WY, Gao J, Lieb W, Shieh K, Colford JM Jr. (2006) Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. J Clin Oncol 24:419–430PubMedGoogle Scholar
  55. 55.
    McCune JS, Hatfield AJ, Blackburn AA, Leith PO, Livingston RB, Ellis GK (2004) Potential of chemotherapy–herb interactions in adult cancer patients. Support Care Cancer 12:454–462PubMedGoogle Scholar
  56. 56.
    McRae S (1996) Elevated serum digoxin levels in a patient taking digoxin and Siberian ginseng. Cmaj 155:293–295PubMedGoogle Scholar
  57. 57.
    Meijerman I, Beijnen JH, Schellens JH (2006) Herb–drug interactions in oncology: focus on mechanisms of induction. Oncologist 11:742–752PubMedGoogle Scholar
  58. 58.
    Miller LG (1998) Herbal medicinals: selected clinical considerations focusing on known or potential drug–herb interactions. Arch Intern Med 158:2200–2211PubMedGoogle Scholar
  59. 59.
    Mishra B, Priyadarsini KI, Bhide MK, Kadam RM, Mohan H (2004) Reactions of superoxide radicals with curcumin: probable mechanisms by optical spectroscopy and EPR. Free Radic Res 38:355–362PubMedGoogle Scholar
  60. 60.
    Mok TS, Yeo W, Johnson PJ, Hui P, Ho WM, Lam KC, Xu M, Chak K, Chan A, Wong H, Mo F, Zee B (2007) A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity. Ann Oncol 18:768–774PubMedGoogle Scholar
  61. 61.
    Molassiotis A, Fernadez-Ortega P, Pud D, Ozden G, Scott JA, Panteli V, Margulies A, Browall M, Magri M, Selvekerova S, Madsen E, Milovics L, Bruyns I, Gudmundsdottir G, Hummerston S, Ahmad AM, Platin N, Kearney N, Patiraki E (2005) Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol 16:655–663PubMedGoogle Scholar
  62. 62.
    Morales A, Pujari B (1975) The choice of estrogen preparations in the treatment of prostatic cancer. Can Med Assoc J 113:865–867PubMedGoogle Scholar
  63. 63.
    Nahleh Z, Tabbara IA (2003) Complementary and alternative medicine in breast cancer patients. Palliat Support Care 1:267–273PubMedCrossRefGoogle Scholar
  64. 64.
    Nielsen I, Pedersen RS (1984) Life-threatening hypokalaemia caused by liquorice ingestion. Lancet 1:1305PubMedGoogle Scholar
  65. 65.
    Nortier JL, Martinez MC, Schmeiser HH, Arlt VM, Bieler CA, Petein M, Depierreux MF, De Pauw L, Abramowicz D, Vereerstraeten P, Vanherweghem JL (2000) Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 342:1686–1692PubMedGoogle Scholar
  66. 66.
    Oh WK, Kantoff PW, Weinberg V, Jones G, Rini BI, Derynck MK, Bok R, Smith MR, Bubley GJ, Rosen RT, DiPaola RS, Small EJ (2004) Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol 22:3705–3712PubMedGoogle Scholar
  67. 67.
    Ono K, Nakane H, Meng ZM, Ose Y, Sakai Y, Mizuno M (1989) Differential inhibitory effects of various herb extracts on the activities of reverse transcriptase and various deoxyribonucleic acid (DNA) polymerases. Chem Pharm Bull (Tokyo) 37:1810–1812Google Scholar
  68. 68.
    Page RL 2nd, Lawrence JD (1999) Potentiation of warfarin by dong quai. Pharmacotherapy 19:870–876PubMedGoogle Scholar
  69. 69.
    Pak E, Esrason KT, Wu VH (2004) Hepatotoxicity of herbal remedies: an emerging dilemma. Prog Transplant 14:91–96PubMedGoogle Scholar
  70. 70.
    Palop-Larrea V, Gonzalvez-Perales JL, Catalan-Oliver C, Belenguer-Varea A, Martinez-Mir I (2000) Metrorrhagia and ginseng. Ann Pharmacother 34:1347–1348PubMedGoogle Scholar
  71. 71.
    Pan KY, Lin JL, Chen JS (2001) Severe reversible bone marrow suppression induced by Selaginella doederleinii. J Toxicol Clin Toxicol 39:637–639PubMedGoogle Scholar
  72. 72.
    Piper JT, Singhal SS, Salameh MS, Torman RT, Awasthi YC, Awasthi S (1998) Mechanisms of anticarcinogenic properties of curcumin: the effect of curcumin on glutathione linked detoxification enzymes in rat liver. Int J Biochem Cell Biol 30:445–456PubMedGoogle Scholar
  73. 73.
    Pittler MH, Ernst E (2003) Systematic review: hepatotoxic events associated with herbal medicinal products. Aliment Pharmacol Ther 18:451–471PubMedGoogle Scholar
  74. 74.
    Rasyid A, Lelo A (1999) The effect of curcumin and placebo on human gall-bladder function: an ultrasound study. Aliment Pharmacol Ther 13:245–249PubMedGoogle Scholar
  75. 75.
    Richardson MA (2001) Biopharmacologic and herbal therapies for cancer: research update from NCCAM. J Nutr 131:3037S–3040SPubMedGoogle Scholar
  76. 76.
    Roberts CS, Baker F, Hann D, Runfola J, Witt C, McDonald J, Livingston ML, Ruiterman J, Ampela R, Kaw OC, Blanchard C (2005) Patient–physician communication regarding use of complementary therapies during cancer treatment. J Psychosoc Oncol 23:35–60PubMedGoogle Scholar
  77. 77.
    Ryu SJ, Chien YY (1995) Ginseng-associated cerebral arteritis. Neurology 45:829–830PubMedGoogle Scholar
  78. 78.
    Saw JT, Bahari MB, Ang HH, Lim YH (2006) Potential drug–herb interaction with antiplatelet/anticoagulant drugs. Complement Ther Clin Pract 12:236–241PubMedGoogle Scholar
  79. 79.
    Seguro AC, Campos SB (2002) Diuretic effect of sodium artesunate in patients with malaria. Am J Trop Med Hyg 67:473–474PubMedGoogle Scholar
  80. 80.
    Senthilnathan P, Padmavathi R, Banu SM, Sakthisekaran D (2006) Enhancement of antitumor effect of paclitaxel in combination with immunomodulatory Withania somnifera on benzo(a)pyrene induced experimental lung cancer. Chem Biol Interact 159:180–185PubMedGoogle Scholar
  81. 81.
    Shah BH, Nawaz Z, Pertani SA, Roomi A, Mahmood H, Saeed SA, Gilani AH (1999) Inhibitory effect of curcumin, a food spice from turmeric, on platelet-activating factor- and arachidonic acid-mediated platelet aggregation through inhibition of thromboxane formation and Ca2+ signaling. Biochem Pharmacol 58:1167–1172PubMedGoogle Scholar
  82. 82.
    Shah RG, Netrawali MS (1988) Evaluation of mutagenic activity of turmeric extract containing curcumin, before and after activation with mammalian cecal microbial extract of liver microsomal fraction, in the Ames Salmonella test. Bull Environ Contam Toxicol 40:350–357PubMedGoogle Scholar
  83. 83.
    Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM, Pirmohamed M, Marnett LJ, Gescher AJ, Steward WP (2001) Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 7:1894–1900PubMedGoogle Scholar
  84. 84.
    Sheu JR, Kan YC, Hung WC, Lin CH, Yen MH (2000) The antiplatelet activity of tetramethylpyrazine is mediated through activation of NO synthase. Life Sci 67:937–947PubMedGoogle Scholar
  85. 85.
    Shu X, McCulloch M, Xiao H, Broffman M, Gao J (2005) Chinese herbal medicine and chemotherapy in the treatment of hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Integr Cancer Ther 4:219–229PubMedGoogle Scholar
  86. 86.
    Shumay DM, Maskarinec G, Kakai H, Gotay CC (2001) Why some cancer patients choose complementary and alternative medicine instead of conventional treatment. J Fam Pract 50:1067PubMedGoogle Scholar
  87. 87.
    Singh H, Maskarinec G, Shumay DM (2005) Understanding the motivation for conventional and complementary/alternative medicine use among men with prostate cancer. Integr Cancer Ther 4:187–194PubMedGoogle Scholar
  88. 88.
    Small EJ, Frohlich MW, Bok R, Shinohara K, Grossfeld G, Rozenblat Z, Kelly WK, Corry M, Reese DM (2000) Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol 18:3595–3603PubMedGoogle Scholar
  89. 89.
    Stiborova M, Frei E, Sopko B, Wiessler M, Schmeiser HH (2002) Carcinogenic aristolochic acids upon activation by DT-diaphorase form adducts found in DNA of patients with Chinese herbs nephropathy. Carcinogenesis 23:617–625PubMedGoogle Scholar
  90. 90.
    Stickel F, Schuppan D (2007) Herbal medicine in the treatment of liver diseases. Dig Liver Dis 39:293–304PubMedGoogle Scholar
  91. 91.
    Stickel F, Seitz HK (2000) The efficacy and safety of comfrey. Public Health Nutr 3:501–508PubMedGoogle Scholar
  92. 92.
    Sun Y (1988) The role of traditional Chinese medicine in supportive care of cancer patients. Recent Results Cancer Res 108:327–334PubMedGoogle Scholar
  93. 93.
    Tagliaferri M, Cohen I, Tripathy D (2001) Complementary and alternative medicine in early-stage breast cancer. Semin Oncol 28:121–134PubMedGoogle Scholar
  94. 94.
    Tatsumura Y, Maskarinec G, Shumay DM, Kakai H (2003) Religious and spiritual resources, CAM, and conventional treatment in the lives of cancer patients. Altern Ther Health Med 9:64–71PubMedGoogle Scholar
  95. 95.
    To KK, Au-Yeung SC, Ho YP (2006) Differential nephrotoxicity of cisplatin and a novel series of traditional Chinese medicine–platinum anticancer agents correlates with their chemical reactivity towards sulfur-containing nucleophiles. Anticancer Drugs 17:673–683PubMedGoogle Scholar
  96. 96.
    Toovey S, Jamieson A (2004) Audiometric changes associated with the treatment of uncomplicated falciparum malaria with co-artemether. Trans R Soc Trop Med Hyg 98:261–267 discussion 268–269PubMedGoogle Scholar
  97. 97.
    Tripathi YB, Tripathi P, Arjmandi BH (2005) Nutraceuticals and cancer management. Front Biosci 10:1607–1618PubMedGoogle Scholar
  98. 98.
    Vanherweghem JL, Depierreux M, Tielemans C, Abramowicz D, Dratwa M, Jadoul M, Richard C, Vandervelde D, Verbeelen D, Vanhaelen-Fastre R et al (1993) Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 341:387–391PubMedGoogle Scholar
  99. 99.
    Vanherweghem LJ (1998) Misuse of herbal remedies: the case of an outbreak of terminal renal failure in Belgium (Chinese herbs nephropathy). J Altern Complement Med 4:9–13PubMedGoogle Scholar
  100. 100.
    Wachtel-Galor S, Tomlinson B, Benzie IF (2004) Ganoderma lucidum (“Lingzhi”), a Chinese medicinal mushroom: biomarker responses in a controlled human supplementation study. Br J Nutr 91:263–269PubMedGoogle Scholar
  101. 101.
    Walker BR, Edwards CR (1994) Licorice-induced hypertension and syndromes of apparent mineralocorticoid excess. Endocrinol Metab Clin North Am 23:359–377PubMedGoogle Scholar
  102. 102.
    Wanachiwanawin D, Piankijagum A, Chaiprasert A, Lertlaituan P, Tungtrongchitr A, Chinabutr P (2006) Ganoderma lucidum: a cause of pseudoparasitosis. Southeast Asian J Trop Med Public Health 37:1099–1102PubMedGoogle Scholar
  103. 103.
    Wang YP, Fu PP, Chou MW (2005) Metabolic activation of the tumorigenic pyrrolizidine alkaloid, retrorsine, leading to DNA adduct formation in vivo. Int J Environ Res Public Health 2:74–79PubMedGoogle Scholar
  104. 104.
    Wang ZY, Nixon DW (2001) Licorice and cancer. Nutr Cancer 39:1–11PubMedGoogle Scholar
  105. 105.
    White M, Verhoef M (2006) Cancer as part of the journey: the role of spirituality in the decision to decline conventional prostate cancer treatment and to use complementary and alternative medicine. Integr Cancer Ther 5:117–122PubMedGoogle Scholar
  106. 106.
    Willetts KE, Ekangaki A, Eden JA (2003) Effect of a ginger extract on pregnancy-induced nausea: a randomised controlled trial. Aust N Z J Obstet Gynaecol 43:139–144PubMedGoogle Scholar
  107. 107.
    Wu K, Jiang L, Cao J, Yang G, Geng C, Zhong L (2007) Genotoxic effect and nitrative DNA damage in HepG2 cells exposed to aristolochic acid. Mutat Res 630:97–102PubMedGoogle Scholar
  108. 108.
    Wu ML, Deng JF, Wu JC, Fan FS, Yang CF (2004) Severe bone marrow depression induced by an anticancer herb Cantharanthus roseus. J Toxicol Clin Toxicol 42:667–671PubMedGoogle Scholar
  109. 109.
    Yang HY, Lin JL, Chen KH, Yu CC, Hsu PY, Lin CL (2006) Aristolochic acid-related nephropathy associated with the popular Chinese herb Xi Xin. J Nephrol 19:111–114PubMedGoogle Scholar
  110. 110.
    Yang L, Li X, Wang H (2007) Possible mechanisms explaining the tendency towards interstitial fibrosis in aristolochic acid-induced acute tubular necrosis. Nephrol Dial Transplant 22:445–456PubMedGoogle Scholar
  111. 111.
    Yates JS, Mustian KM, Morrow GR, Gillies LJ, Padmanaban D, Atkins JN, Issell B, Kirshner JJ, Colman LK (2005) Prevalence of complementary and alternative medicine use in cancer patients during treatment. Support Care Cancer 13:806–811PubMedGoogle Scholar
  112. 112.
    Yuen MF, Tam S, Fung J, Wong DK, Wong BC, Lai CL (2006) Traditional Chinese medicine causing hepatotoxicity in patients with chronic hepatitis B infection: a 1-year prospective study. Aliment Pharmacol Ther 24:1179–1186PubMedGoogle Scholar
  113. 113.
    Zhou SF, Xue CC, Yu XQ, Wang G (2007) Metabolic activation of herbal and dietary constituents and its clinical and toxicological implications: an update. Curr Drug Metab 8:526–553PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  1. 1.Division of Hematology/Oncology, Department of MedicineThe University of Hong Kong, Queen Mary HospitalPokfulamHong Kong
  2. 2.Department of MedicineThe University of Hong KongPokfulamHong Kong

Personalised recommendations